HDAC inhibition as a therapeutic strategy in myocardial ischemia/reperfusion injury

Min Xie, Yida Tang, Joseph A. Hill

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Reperfusion injury during myocardial infarction accounts for approximately half of final infarct size. Whereas this has been known for decades, efficacious therapy targeting reperfusion injury remains elusive. Many proteins are subject to reversible acetylation, and drugs targeting enzymes that govern these events have emerged in oncology. Among these, small molecules targeting protein deacetylating enzymes, so-called histone deacetylases (HDACs), are approved for human use in rare cancers. Now, work emerging from multiple laboratories, and in both mice and large animals, has documented that HDAC inhibition using compounds approved for clinical use confers robust cardioprotection when delivered at the time of myocardial reperfusion. Here, we summarize the key underpinnings of this science, discuss potential mechanisms, and provide a framework for a first-in-human clinical trial.

Original languageEnglish (US)
Pages (from-to)188-192
Number of pages5
JournalJournal of Molecular and Cellular Cardiology
StatePublished - Apr 2019

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'HDAC inhibition as a therapeutic strategy in myocardial ischemia/reperfusion injury'. Together they form a unique fingerprint.

Cite this